Maja Cemazar
Overview
Explore the profile of Maja Cemazar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
239
Citations
3125
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ursic Valentinuzzi K, Kamensek U, Brezar S, Heranney C, Komel T, Bucek S, et al.
Front Immunol
. 2025 Feb;
16:1470432.
PMID: 40007542
Introduction: In addition to its direct cytotoxic effects, ablative therapies as electrochemotherapy (ECT) can elicit indirect antitumor effects by triggering immune system responses. Here, we comprehensively analyzed this dual effectiveness...
2.
De Robertis M, Bozic T, Santek I, Marzano F, Markelc B, Silvestris D, et al.
Mol Ther Nucleic Acids
. 2025 Feb;
36(1):102448.
PMID: 39967849
Gene electrotransfer (GET) has recently emerged as an effective nonviral approach for plasmid DNA (pDNA) delivery in gene therapy for several pathologies, including cancer. Multiple mechanisms have been identified that...
3.
Scattolin T, Cavarzerani E, Alessi D, Mauceri M, Botter E, Tonon G, et al.
Dalton Trans
. 2025 Feb;
54(11):4685-4696.
PMID: 39967474
High-Grade Serous Ovarian Cancer (HGSOC) is the most common and lethal subtype of ovarian cancer, known for its high aggressiveness and extensive genomic alterations. Typically diagnosed at an advanced stage,...
4.
Strojan P, Jesenko T, Omerzel M, Jamsek C, Groselj A, Tratar U, et al.
Eur J Surg Oncol
. 2025 Jan;
51(5):109574.
PMID: 39799833
Introduction: In the treatment of cancer, immunomodulatory approaches are developed to support the organism in fighting cancer or to enhance the immunomodulatory effects of local ablative techniques. To this end,...
5.
Muir T, Wohlgemuth W, Cemazar M, Bertino G, Groselj A, Ratnam L, et al.
Radiol Oncol
. 2024 Nov;
58(4):469-479.
PMID: 39608012
Background: Bleomycin ElectroScleroTherapy (BEST) is a new approach in the treatment of vascular malformations. After bleomycin is administered to the malformation, electric pulses are applied to the target area to...
6.
Markelc B, Jesenko T, Brezar S, Omerzel M, Tratar U, Rencelj A, et al.
Sci Rep
. 2024 Sep;
14(1):22288.
PMID: 39333733
Immunotherapeutic drugs are promising medicines for cancer treatment. A potential candidate for immunotherapy is interleukin-12 (IL-12), a cytokine well known for its ability to mediate antitumor activity. We developed a...
7.
Lozar T, Gersak K, Cemazar M, Grasic Kuhar C, Jesenko T
Radiol Oncol
. 2024 Sep;
58(3):458.
PMID: 39287172
No abstract available.
8.
Vake T, Snoj T, Cemazar M, Tratar U, Stupan U, Seliskar A, et al.
Lab Anim
. 2024 Aug;
58(6):602-611.
PMID: 39157982
Increasing use of pigs as models in translational research, and growing focus on animal welfare are leading to better use of effective analgesics and anaesthetics when painful procedures are performed....
9.
Bortolamiol E, Mauceri M, Piccolo R, Cavarzerani E, Demitri N, Donati C, et al.
J Med Chem
. 2024 Aug;
67(16):14414-14431.
PMID: 39119630
In this study, we synthesized novel Pd(II)-indenyl complexes using various -heterocyclic carbene (NHC) ligands, including chelating NHC-picolyl, NHC-thioether, and diNHC ligands, and two monodentate NHCs. Transmetalation reactions between a Pd(II)-indenyl...
10.
Palazzolo S, Saorin G, Corona G, Granchi C, Tuccinardi T, Kamensek U, et al.
Eur J Pharm Biopharm
. 2024 Jul;
203:114397.
PMID: 38972466
Monoacylglycerol lipase (MAGL) is a promising target for cancer therapy due to its involvement in lipid metabolism and its impact on cancer hallmarks like cell proliferation, migration, and tumor progression....